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Abstract
Background: Cerebellar atrophy and developmental delay are commonly associated features in large numbers of
genetic diseases that frequently also include epilepsy. These defects are highly heterogeneous on both the genetic
and clinical levels. Patients with these signs also typically present with non-specific neuroimaging results that can
help prioritize further investigation but don’t suggest a specific molecular diagnosis.
Methods: To genetically explore a cohort of 18 Egyptian families with undiagnosed cerebellar atrophy identified on
MRI, we sequenced probands and some non-affected family members via high-coverage whole exome sequencing
(WES; >97 % of the exome covered at least by 30x). Patients were mostly from consanguineous families,
either sporadic or multiplex. We analyzed WES data and filtered variants according to dominant and recessive
inheritance models.
Results: We successfully identified disease-causing mutations in half of the families screened (9/18). These
mutations are located in seven different genes, PLA2G6 being the gene most frequently mutated (n = 3).
We also identified a recurrent de novo mutation in the KIF1A gene and a molybdenum cofactor deficiency
caused by the loss of the start codon in the MOCS2A open-reading frame in a mildly affected subject.
Conclusions: This study illustrates the necessity of screening for dominant mutations in WES data from
consanguineous families. Our identification of a patient with a mild and improving phenotype carrying a
previously characterized severe loss of function mutation also broadens the clinical spectrum associated with
molybdenum cofactor deficiency.
Keywords: Cerebellum atrophy, Intellectual disability, Exome sequencing, Molybdenum cofactor deficiency,
MOCS2, KIF1A
* Correspondence: vincent.cantagrel@inserm.fr
†Equal contributors
2INSERM UMR 1163, Laboratory of Molecular and Pathophysiological Bases of
Cognitive Disorders, Paris, France
3Paris Descartes – Sorbonne Paris Cité University, Imagine Institute, Paris,
France
Full list of author information is available at the end of the article
© 2016 Megahed et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Megahed et al. Orphanet Journal of Rare Diseases  (2016) 11:57 
DOI 10.1186/s13023-016-0436-9
Background
Atrophy and hypoplasia of the cerebellum are neuro-
radiological findings identified in pediatric-onset cere-
bellar ataxias and generally associated with imbalance,
poor coordination and developmental delay. Heredi-
tary cerebellar atrophy in childhood is a clinically and
genetically heterogeneous group of conditions. They in-
clude a vast number of differential diagnoses with overlap-
ping clinical findings such as intellectual disability and
epilepsy [1, 2].
The specificity of cerebellar atrophy as a neuroradio-
logical finding has been formerly discussed [2]. In asso-
ciation with a careful initial clinical evaluation, the
characterization of cerebellar atrophy and/or hypoplasia
by MRI is currently used to prioritize specialized inves-
tigations and potential diagnosis [1, 3].
The most frequent causes of early-onset cerebellar
atrophy include mitochondrial disorders, neuronal cer-
oid lipofuscinosis, congenital disorders of glycosylation,
ataxia telangiectasia and infantile neuroaxonal dystrophy
[1]. The reason for the exquisite sensitivity of the cere-
bellum to defects in general cellular processes involving
mitochondria, protein glycosylation or lysosomes is not
known. The loss of Purkinje cells could play a central
role in the pathology of many cerebellar ataxias as they
are highly metabolic cells and these cells are the only
out-put of the cerebellum.
This group of disorders includes an ever-increasing
number of very rare conditions and currently over 169
OMIM clinical synopses are associated with cerebellar
atrophy (OMIM December 2015). The overlapping
clinical features of these numerous conditions often
prevent a rapid and accurate clinical and genetic diagnosis
and for more than half of the patients with childhood-
onset cerebellar atrophy, a molecular diagnosis is not
available [3].
Additionally, many of these conditions start with motor
and cognitive delay or deterioration but some diagnostic
criteria appear later during the developmental course
of the disease. For example, in the case of PLA2G6-
associated neurodegeneration (PLAN), brain iron accu-
mulation is generally not detected in the early stages of
the disease [4, 5].
In such situations whole exome sequencing (WES)
has been able to accelerate molecular diagnosis, better
delineate the clinical spectrum associated with specific
genetic defects and improve patient management [6, 7].
In this study, we assessed a cohort of 18 families of
Egyptian origin with childhood-onset cerebellar atrophy
and developmental delay. We analyzed them for both
recessive and dominant variants and successfully iden-
tified disease-causing mutations in half of the families
(9/18). This study highlights the importance of searching
for dominant mutations in consanguineous families and
broadens the clinical spectrum associated with some
cerebellar conditions, including molybdenum cofactor
deficiency.
Methods
Subject information
We studied 18 families including 12 sporadic cases (67 %)
and 16 families with reported consanguinity (89 %). For
half of these families only the proband was exome se-
quenced and for the other half we performed trio exome
sequencing. The mean age was 4.6 years (Standard devi-
ation 3.2 years) at the time of the study. Patients had
various degrees of cerebellar atrophy identified on MRI,
involving mainly the vermis or the entire cerebellum. Both
static and progressive conditions were included. Written
informed consent was obtained from all families, and
the study was approved by the ethics committee of the
National Research Center in Cairo.
Whole exome sequencing
DNA was extracted from blood and the sequencing core
facility at the Imagine Institute performed WES. Briefly,
WES libraries were prepared from 3 μg of genomic
DNA sheared by ultrasonication (Covaris S220 Ultraso-
nicator). Exome capture was performed with the 51 Mb
SureSelect Human All Exon kit V5 (Agilent technolo-
gies). Sequencing of the WES libraries was carried out
on a HiSeq2500 (Illumina). Paired-end reads were gener-
ated and mapped on the human genome reference using
Burrows-Wheeler Aligner (BWA) [8]. The mean depth
of coverage obtained for each sample was > 160x with
>97 % of the exome covered at least 30x. SNP and indel
calling was made using GATK tools. Families CIE3, 4, 5,
8, 11, 12, 13, 18 and 19 (n = 9; 50 %) were investigated
by trio WES and for families CIE1, 2, 7, 9, 14, 16, 17, 21,
29 (n = 9; 50 %) WES was only performed for the
proband.
Bioinformatics, databases
A variant filtering pipeline was systematically applied to
narrow down the number of putative causative variants.
All the possible inheritance patterns were tested. Briefly,
common (>1 % minor allele frequency) variants were
filtered out by using dbSNP, 1000 genomes databases
and our in house exome collection, which includes more
than 7000 exomes. Functional (protein-altering) alleles
were prioritized versus non-functional. Potentially patho-
genic variants in known disease genes were identified if
flagged as damaging by polyphen2 (http://genetics.bwh.
harvard.edu/pph2/), Sift (http://sift.jcvi.org/) or mutation
taster (http://www.mutationtaster.org/). Remaining vari-
ants were compared with those in the public databases
EXAC (http://exac.broadinstitute.org/) and EVS (http://
evs.gs.washington.edu/EVS/) exome database. The presence
Megahed et al. Orphanet Journal of Rare Diseases  (2016) 11:57 Page 2 of 8
of candidate recessive variants in homozygous intervals
was checked by identifying predicted regions of SNP
homozygosity from exome data with the unifiedgenoty-
per tool from GATK (https://www.broadinstitute.org/
gatk/). In order to identify fully penetrant dominant
mutation in singleton WES data we used the following
method. We filtered out variants that were present in
control individuals from our in house exome database
and not predicted to be pathogenic by at least two pre-
diction programs: PolyPhen, SIFT or Mutation-Taster.
When a single rare variant predicted to be deleterious
was observed in a single known cerebellar atrophy gene
and associated with a dominant mode of inheritance, it
was considered as potential candidate. When the same
rare variant has been previously associated with disease,
this was considered strong evidence that it was likely to
be pathogenic. We validated potential de novo muta-
tions by using Sanger sequencing on patients and par-
ents DNA. However considering the large number of
variants generated by this method, it is considered effi-
cient only for the identification of mutations in known
disease genes.
Results
Homozygous, compound heterozygous and potential de
novo mutations were investigated in all families. We
identified pathological mutations in 7 genes within nine
families (9/18; 50 %): a homozygous TPP1 mutation
c.790C > T (NM_000391.3) p.Gln264* in family CIE7;
a homozygous EXOSC3 mutation c.395A > C (NM_
016042.3) p.Asp132Ala in CIE9; a homozygous PLA2G6
c.2070_2072del (NM_003560.2) p.Val691del mutation in
families CIE11 and CIE13; a homozygous MOCS2 c.3G >A
(NM_176806.3) p.Met1? mutation in CIE12; a homozygous
SURF1 mutation c.237G >A (NM_003172.3) p.Trp79* in
CIE16; a homozygous MFSD8 c.1213C >T (NM_152778.2)
p.Gln405* mutation in family CIE17; a de novo KIF1A mu-
tation c.173C >T (NM_001244008.1) p.Ser58Leu in family
CIE21 and a homozygous PLA2G6 mutation c.1613G >A
(NM_003560.2) p.Arg538His in family CIE29. Mutation
segregation was checked by Sanger sequencing in all avail-
able samples (indicated by a star on Fig. 1).
Clinical findings in the affected individuals with mo-
lecular diagnosis are summarized in Table 1. Previously
described mutations were identified in six genes TPP1,
EXOSC3, PLA2G6, MOCS2 and SURF1 and KIF1A. The
PLA2G6 gene was the most frequently mutated gene
and the c.2070_2072del mutation was identified in two
families in our WES data. The identification of this
recurrent mutation during the course of the project, led
us to implement Sanger sequencing of this specific allele
and only samples negative for this prescreen where sub-
mitted to WES. Using this method, we could identify a
third family with the same c.2070_2072del mutation. In
total, this 3 bp deletions accounts for 15 % of all the
families tested in this study. The identification of MFSD8
mutations in family CIE17 was consistent with an early
onset of ceroid lipofuscinosis, neuronal 7 (CLN7) associ-
ated with cortical and cerebellar atrophy and an enlarge-
ment of the cerebral ventricles in the proband (Fig. 2a-c),
a phenotype that usually manifests between 2 and 6 years
old [9]. In family CIE21, we identified a recurrent de novo
mutation in the KIF1A gene. This mutation is predicted to
disrupt some hydrogen bonds in the ATP binding domain
(Additional file 1: Figure S1) and results in cerebellar atro-
phy (Fig. 2d-f) and epilepsy (Table 1). In family CIE12, we
found biallelic mutations in the initiation codon of the
MOCS2A open reading frame of the bicistronic MOCS2
gene. Mutations in this gene cause Molybdenum Cofactor
(MoCo) deficiency, a severe neonatal inborn error of
metabolism usually associated with subcortical multicystic
lesions and death during early childhood stage [10]. Pa-
tient CIE12-A2 was born to consanguineous parents and
was affected since birth. At 3.8 years, she presented with
delayed speech and delayed walking. She had wide based
gait, hyperreflexia and hypertonia with the left side of her
body being more affected than the right. The mother had
Fig. 1 Pedigrees of families with identified disease-causing genes. A
star indicates individuals with DNA available for segregation test and
arrowheads point to the samples sequenced by WES
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Table 1 Clinical presentation, laboratory investigation and exome sequencing result for 10 patients with undiagnosed cerebellar atrophy
CIE7-A1 CIE9-A1 CIE11-A1 CIE12-A2 CIE13-A1/A2 CIE16-A1 CIE17-A1 CIE-21-A1 CIE-29-A1
Gender M F F F M F F F M
Gene mutated TPP1 EXOSC3 PLA2G6 MOCS2 PLA2G6 SURF1 MFSD8 KIF1A PLA2G6
Genbank reference NM_000391.3 NM_016042.3 NM_003560.2 NM_176806.3 NM_003560.2 NM_003172.3 NM_152778.2 NM_001244008.1 NM_003560.2
Mutation cDNA level c.790C > T c.395A > C c.2070_2072del c.3G > A c.2070_2072del c.237G > A c.1213C > T c.173C > T c.1613G > A
Mutation protein level p.Q264* p.D132A p.V691del p.M1? p.V691del p.W79* p.Q405* p.S58L p.R538H
Final diagnosis CLN2 Late
infantile
Mild PCH type
1B
PLAN/INAD Mild MoCo
deficiency
PLAN/INAD LEIGH SYNDROME CLN7 AD ID PLAN/INAD
Age of onset (years.months) 3.1 1 0.9 Neonatal 1.6/1.0 1 0.6 2.0 1.5
Last follow-up (years.months) 4.6 1.9 3.0 6.0 4.0/2.0 4.7 3.6 5.0 3.6
Initial symptom Convulsions Developmental
delay
Convulsions Developmental
delay
Convulsions Gait disturbance Developmental
delay
Gait disturbance Developmental
regression
Development
Developmental delay + + + + + + + + +
Motor developmental
delay
+ + + + +/++ + + + +
Social development
delay
+ + + + +/++ + ++ (autistic features) + +
Progressive condition + - Mildy progressive - + + + - +
Seizures
Description Focal epileptic
activity
GTC Focal Right-temporal
discharges, GTC
Left fronto-temporal
epileptogenic
dysfunction
Focal, GTC GTC Right frontal
epileptogenic
focus, Akinetic
fits
Right-temporal
activity, intractable
epilepsy
GTC
Neurological Findings
Hypotonia + + + - (Hypertonia) + + + + +
Nystagmus - + + - + + - - +
Wide-based, staggering
gait
+ + Enable to walk Wide based gait + Tetubation, ataxia + Wide-based,
staggering gait
Tetubation,ataxia
Peripheral neuropathy - + + - + + - + +
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Table 1 Clinical presentation, laboratory investigation and exome sequencing result for 10 patients with undiagnosed cerebellar atrophy (Continued)
MRI
Cerebellum:Hypoplasia/
Progressive or fixed
Atrophy
Atrophy/
hypoplasia
Atrophy Atrophy,hypoplasia,
dilated cisterna
magna
Atrophy Atrophy Atrophy + abnormal
signal intensity
Atrophy Atrophy Atrophy
Brainstem - - - - - Abnormal signal
intensity as well as
in BG
- - -
Cerebral cortex Mild cortical
atrophy
- - Right frontal
arachnoid cyst, mild
frontal lobe atrophy
Mild cortical
atrophy/-
- Atrophy - -
Ventricular system - - Dilated - Moderate
dilatation
- Mild dilatation - -
Facial dysmorphism - Squint - Mild dysmorphism - - - - -
Ophtalmologic finding Fundus exam:
Macular lesion
- - - - - - - -
Relevant metabolic result High Plasma
S-Sulphocysteine
level and high
plamsa Xhantine
level (see text)
Plasma lactate in
the normal range
Blood ammonia:
62.2 μmol/L
(normal 15–45);
blood lactate:
20.6 mmol/L
(normal = 0.5-2.2)
Abbreviations: GTC generalized tonic-clonic, PCH pontocerebellar hypoplasia, PLAN PLA2G6-associated neurodegeneration, INAD infantile neuroaxonal dystrophy, MoCo Molybdenum cofactor, CLN Ceroid lipofuscinosis
neuronal, AD autosomal dominant, ID intellectual disability, BG basal ganglia
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an uncomplicated pregnancy although she was exposed
to X-Rays when she was one month pregnant. This pa-
tient has two unaffected siblings, one deceased brother
and an older brother who suffered from global develop-
ment delay since birth and mild cortical brain atrophy
on MRI associated with abnormal EEG. At 6.0 years,
patient CIE12-A2 appeared to improve gradually. Des-
pite some residual unsteadiness, she can walk, read and
memorize short sentences. Her initial investigations
included CT and MRI, which revealed right frontal
arachnoid cyst, mild right frontal lobe brain atrophy
and cerebellar atrophy (Fig. 2g-i). A follow up CT two
years latter indicated that the arachnoid cyst had slightly
resolved. Her EEG revealed left fronto-temporal epilepto-
genic dysfunction. The follow up EEGs showed improve-
ment in the epileptogenic bursts probably as a result of
the antiepileptic therapy she is receiving. The molecular
diagnosis was supported by the blood tests results, con-
sistent with Molybdenum Cofactor deficiency. Plasma
S-Sulphocysteine level was 309 micromol/mmol (Con-
trol value <10) and Plasma Xanthine 1291 micromol/mmol
(Control value <40). She is currently receiving sodium
valproate (30mh/kg), Levitiracetam (20 mg/kg), omega 3
supplements, and IM (intra-muscular) B complex.
Discussion
In this study, we explored sporadic and multiplex Egyptian
families with early-onset cerebellar atrophy associated
with developmental delay by using high-coverage whole
exome sequencing. Our analysis included the investigation
of recessive and dominant variants and we identified
pathogenic mutations in 50 % of the 18 families studied.
Previous reports that focused on sporadic and inherited
cerebellar atrophies [11] or ataxias [12] and obtained
Fig. 2 Brain MRI scans from families CIE17, CIE21 and CIE12. a-c MRIs of case CIE17-A1 (MFSD8 mutation) at 3 years. a Midline Sagittal T2-weighted
image demonstrating enlarged cerebellar folia (arrow head) and thin corpus callosum. Ventricular system dilatation (star) is visible on coronal T1 image
(b). d-f MRIs of patient CIE-21-A1 (KIF1A mutation) at 5 years showing cerebellar atrophy (arrowhead) on midline sagittal T2 (d), coronal T1 (e) and axial
T1 (f) images. g-i MRIs of patient CIE12-A2 (MOCS2 mutation) with evidence of cerebellar vermis atrophy (arrowhead) on sagittal T1 image (g)
and Right frontal arachnoid cyst (red arrow) visible on axial T2 scan (h)
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comparable success rates of 39.1 and 41 % respectively, in
the identification of pathological mutations.
The absences of diagnosis for half of the cohort could
be explain with the following reasons. Despite high
depth of sequencing (mean depth of coverage > 160x),
exome capture does not provide complete coverage of
all coding regions of the genome, particularly those with
GC-rich regions. Moreover, large genomic rearrangements
and trinucleotide repeat sequences are not reliably de-
tected from exome-capture data. It is also possible that
some causal variants will reside within non-coding regula-
tory regions. Some of these issues will be resolved by
whole genome sequencing, although not without substan-
tial additional cost and bioinformatics analyses. However
it is likely that mutation in yet unknown cerebellar
atrophy genes contribute significantly to these diseases. In
this study, half of the patients were explored by using trio
WES and the other half by singletons WES. Trio WES did
not improve the diagnosis rate but considerably decreased
the number of Sanger cosegregation analyses. It impacted
specially de novo mutations analysis but singleton WES
did not prevent de novo mutation identification as illus-
trated with the KIF1A gene mutation. One of the clear
advantages of trio WES is its ability to point to a limited
number of variants located in novel candidate disease-
causing genes when mutations located in known disease
gene are absent. The identification of KIF1A de novo
mutation highlights the importance of considering not
only recessive inheritance patterns when analyzing con-
sanguineous exomes despite the presence of extensive
regions of homozygosity (data not shown). This finding
identifies p.Ser58Leu as a recurrent KIF1A mutation [13]
and indicates that cerebellar atrophy is the main MRI fea-
ture associated with this allele. Several typical symptoms
of infantile-onset PLA2G6-associated neurodegeneration
(PLAN) are not always observed before 4 years, such as
optic atrophy, electroencephalogram fast rhythms and
amyotrophy [4], making very early diagnosis more diffi-
cult. PLA2G6 is the most frequently mutated gene in this
cohort; 3 families were identified with the same homozy-
gous mutation previously described as a founder mutation
in Mediterranean countries [4]. This observation suggests
that the p.Val691del allele is an especially common cause
of PLAN in the Egyptian population. Among other clinical
symptoms, patients with this mutation shared the asso-
ciation of development delay or regression with cere-
bellar atrophy, epilepsy and nystagmus. Mutations in
the MOCS2 genes cause MoCo deficiency type B, which
is currently untreatable [14]. These mutations can occur
in one of the two open-reading frames (i.e., MOCS2A and
MOCS2B) of this bi-cistronic gene and are generally asso-
ciated with untreatable seizures, multiple cystic cavities
on MRI and death at early age [10]. Milder cases have
been reported to be associated with a hypomorphic
allele [15] or mutations involving a non-constitutively
spliced exon [16]. Strikingly, the p.Met1? mutation
identified in MOCS2A has been tested in vitro and
shown to abolish translation [17]. This result highlights
the existence of mild presentations of MoCo syndrome,
potentially detectable with plasma sulfite and xanthine
screening of patients with undiagnosed cerebellar atro-
phy, developmental delay and isolated arachnoid cyst.
Conclusions
Our study emphasizes the benefits of whole exome se-
quencing to efficiently diagnose early-onset cerebellar
atrophy defects, to better delineate the clinical spectrum
associated with these disorders and to open the way for
the identification of new disease genes.
Ethics approval and consent to participate and for
publication
Written informed consent was obtained from all families,
and the study was approved by the ethics committee of
the National Research Center in Cairo.
Additional file
Additional file 1: Figure S1. Modeling of the p.S58L mutation using
the crystal structure of the motor domain of human KIF1A (PDB number
1VFV). The image was generated using PyMOL (http://www.pymol.org).
The side-chain of Ser58 is involved in inferred hydrogen bonds (arrow)
with other amino-acids located in the ATP-binding pocket (A). These
interactions are predicted to be disrupted by the mutation (B) including
the hydrogen bonds with the highly conserved Arginine 11 that interacts
with ATP through a molecule of water. (JPG 499 kb)
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MoCo: molybdenum cofactor; PLAN: PLA2G6-associated neurodegeneration;
WES: whole exome sequencing.
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